The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Managing the challenges associated with continuous BCMA-directed therapy in multiple myeloma
Sundar Jagannath, MD, Tisch Cancer Institute at Mount Sinai, New York, NY, discusses the challenges with BCMA-directed therapies in patients with multiple myeloma, noting that continuous BCMA-directed therapy can lead to downregulation or mutation due to selective pressure. He suggests using alternative targets such as GPRC5D or FcRH5, and highlights the importance of monitoring patients for soluble BCMA and using immunohistochemistry to guide therapy choices. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
